dnazyme การใช้

• This was the first report of the clinical use of a DNAzyme.
• In both trials, there were no adverse events due to DNAzyme.
• The logic gates are made of the E6 Deoxyribozymes ( or DNAzyme ) which react to specific oligonucleotide input.
• There was demonstrable efficacy noted in nasopharyngeal cancer patients injected with LMP1 DNAzyme and allergic asthma patients following GATA3 DNAzyme inhalation.
• There was demonstrable efficacy noted in nasopharyngeal cancer patients injected with LMP1 DNAzyme and allergic asthma patients following GATA3 DNAzyme inhalation.
• Remarkably, researchers have engineered a highly selective sodium-specific DNAzyme and demonstrated its application in detection of sodium in live cells.
• Upon reaction, the DNAzyme cleaves the substrate producing an increase in red or green fluorescence, depending on whether it is the computer's or the human's turn respectively.
• Yet, DNAzymes that catalyze RNA cleavage reaction are the most extensively explored ones . 10-23 DNAzyme, discovered in 1997, is one of the most studied catalytic DNAs with clinical applications as a therapeutic agent.
• Several metal-specific DNAzymes have been reported including the GR-5 DNAzyme ( lead-specific ), the CA1-3 DNAzymes ( copper-specific ), the 39E DNAzyme ( uranyl-specific ) and the NaA43 DNAzyme ( sodium-specific ).
• Several metal-specific DNAzymes have been reported including the GR-5 DNAzyme ( lead-specific ), the CA1-3 DNAzymes ( copper-specific ), the 39E DNAzyme ( uranyl-specific ) and the NaA43 DNAzyme ( sodium-specific ).
• Several metal-specific DNAzymes have been reported including the GR-5 DNAzyme ( lead-specific ), the CA1-3 DNAzymes ( copper-specific ), the 39E DNAzyme ( uranyl-specific ) and the NaA43 DNAzyme ( sodium-specific ).
• The outcome of two other clinical trials evaluating DNAzymes performed in Asia and Europe were reported in 2014 and 2015, the former assessing a Epstein Barr virus latent membrane protein 1 targeting DNAzyme and the latter a DNAzyme targeting the transcription factor GATA3 which involved 7 trial sites.
• The outcome of two other clinical trials evaluating DNAzymes performed in Asia and Europe were reported in 2014 and 2015, the former assessing a Epstein Barr virus latent membrane protein 1 targeting DNAzyme and the latter a DNAzyme targeting the transcription factor GATA3 which involved 7 trial sites.
• This was later followed by numerous other independent, some multi-center, clinical trials evaluating DNAzymes in humans, including DNAzymes targeting EBV-LMP1 in patients with nasopharyngeal cancer and DNAzymes targeting another nuclear transcription factor GATA3 in patients with allergic asthma demonstrating DNAzyme efficacy and safety.